Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial

Laurent-Puig, P, Paget-Bailly, S, Vernerey, D et al. (12 more authors) (2015) Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial. In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .

Metadata

Authors/Creators:
  • Laurent-Puig, P
  • Paget-Bailly, S
  • Vernerey, D
  • Vazart, C
  • Decaulne, V
  • Fontaine, K
  • Rousseau, F
  • Elliott, F
  • Quirke, P
  • Richman, S
  • Seligman, J
  • Seymour, MT
  • Bonnetain, F
  • Liebaert, F
  • Thiebaut, R
Dates:
  • Published: 20 May 2015
  • Accepted: 27 March 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Feb 2016 10:08
Last Modified: 05 Feb 2016 10:08
Published Version: http://meeting.ascopubs.org/cgi/content/abstract/3...
Status: Published
Publisher: American Society of Clinical Oncology
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export